Cannabis News
Shrooms Legalized Before Weed? – FDA Posts Guidelines for Doing Research on Psychedelics
Published
1 year agoon
By
admin
An important step has been taken toward the acceptance and legitimacy of psychedelic therapies with the Food and Drug Administration (FDA) release of a ground-breaking draft guidance addressing the special issues investigating psychedelics for therapeutic reasons. This change occurs when municipalities and states nationwide push more for the study and control of drugs like psilocybin and MDMA. The FDA’s draft guidance provides researchers with a framework to design clinical trials that yield interpretable results, supporting the development of psychedelic medicines. As the draft undergoes a public comment period, stakeholders can shape the final guidance, ensuring it incorporates diverse perspectives and expertise. As the therapeutic potential of psychedelics continues to receive attention, this advice paves the way for a new era of scientific investigation and the potential creation of novel treatments for mental health illnesses.
The FDA’s Draft Guidance on Psychedelic Research:
The release of the FDA’s draft guidance on psychedelic research marks a significant milestone in mental health treatment. The 14-page document provides researchers with a comprehensive framework to conduct studies on psychedelic drugs, which have shown initial promise in treating mood, anxiety, and substance use disorders. Covering various aspects of drug development, the guidance offers insights into trial conduct, data collection, subject safety, and new drug application requirements. By outlining the unique challenges inherent in designing psychedelic drug development programs, the FDA aims to assist researchers in designing studies that yield reliable and interpretable results, supporting future drug applications.
Researchers exploring the therapeutic potential of psychedelics face distinct considerations compared to traditional pharmaceutical research. The draft guidance emphasizes the psychoactive nature of many psychedelics, which sets them apart from conventional medicines. This characteristic increases the potential for abuse and necessitates careful consideration throughout drug development. Moreover, the guidance acknowledges the regulatory complexities associated with entheogenic plants and fungi like psilocybin, classified as Schedule I drugs. Researchers must navigate a more complex registration process with the DEA to obtain these substances for study purposes. The FDA’s guidance provides recommendations on addressing these regulatory challenges effectively.
The draft guidance also underscores the importance of ensuring subject safety during psychedelic research. Given the unique characteristics of psychedelics, researchers must develop safety monitoring strategies tailored to these substances. Additionally, the guidance highlights the significance of characterizing dose-response relationships and evaluating the durability of treatment effects. These considerations help establish the effectiveness and long-term impact of psychedelic therapies. Recognizing the integral role of psychotherapy in psychedelic drug development, the guidance advises researchers to carefully integrate psychotherapy into psychedelic-assisted treatments while minimizing bias in subsequent therapy sessions. By addressing these factors, the FDA aims to enhance the quality and validity of research outcomes in psychedelic-assisted therapy.
Unique Considerations in Psychedelic Research:
The FDA’s draft guidance on psychedelic research sheds light on the unique considerations researchers must address when studying psychedelic substances. A significant aspect highlighted in the guidance is the psychoactive nature of these compounds. Unlike traditional medications, psychedelics induce profound alterations in perception, cognition, and mood, necessitating careful management of the acute experience during clinical trials. Researchers must develop innovative methodologies and measures to capture the therapeutic effects of psychedelics while accounting for the subjective and context-dependent nature of the psychedelic experience. This entails designing studies that can effectively evaluate the safety and efficacy of these substances in a controlled and standardized manner.
In addition to the psychoactive effects, the regulatory landscape surrounding psychedelic substances presents a distinct challenge for researchers. Entheogenic plants and fungi, such as psilocybin, fall under Schedule I classification according to the Controlled Substances Act. This classification imposes stringent regulations and complicates obtaining these substances for research purposes. The FDA provides researchers with recommendations and guidance on navigating the regulatory hurdles associated with Schedule I substances, ensuring compliance with legal and ethical requirements while facilitating access to these compounds for research.
The guidance emphasizes the importance of subject safety in psychedelic research. Given the unique effects and potential risks associated with psychedelics, researchers must establish robust safety protocols and evaluate the risk-benefit profile of their studies. The guidance emphasizes the need for comprehensive safety monitoring throughout the treatment process, including pre-session preparation, administration, and post-session integration and support.
The Impact of FDA Guidance on Psychedelic-Assisted Therapy
The release of the FDA’s draft guidance on psychedelic research carries significant implications for the emerging field of psychedelic-assisted therapy. With growing interest and promising results, this therapeutic approach combines the administration of psychedelics with psychotherapy to treat various mental health conditions. The FDA’s guidance acknowledges this innovative treatment modality and offers considerations specifically tailored to conducting clinical trials in psychedelic-assisted therapy.
One key focus of the guidance is the importance of maintaining treatment blinding in clinical trials. Since therapists monitoring the sessions can often discern the treatment assignment based on the subject’s behavior, it is crucial to minimize potential biases. The guidance suggests that in-session monitors should not be involved in post-session psychotherapy to prevent their knowledge of the treatment from influencing subsequent therapy sessions. By implementing strategies to ensure blinding, researchers can uphold the integrity of the trial and obtain more reliable and unbiased results.
Additionally, the FDA’s guidance underscores the significance of exploring the role of psychotherapy within psychedelic-assisted therapy. Psychedelics enhance the therapeutic process by facilitating introspection, emotional breakthroughs, and personal insights. Understanding the interplay between the psychedelic experience and psychotherapy is vital for optimizing treatment outcomes. The guidance encourages researchers to incorporate appropriate psychotherapeutic techniques and develop protocols that effectively integrate the unique effects of psychedelics into the therapeutic process.
Moreover, the draft guidance emphasizes the importance of characterizing dose-response relationships and treatment durability in psychedelic-assisted therapy. Psychedelics often exhibit dose-dependent effects, meaning the therapeutic outcomes may vary based on the dosage. Researchers are encouraged to investigate the optimal dosage range for medicinal purposes. Additionally, evaluating the durability of treatment effects is crucial to determine the long-term benefits and sustainability of psychedelic-assisted therapy. By comprehensively studying dose-response relationships and treatment durability, researchers can refine treatment protocols and better understand these substances’ therapeutic potential.
Bottom Line
The FDA’s release of draft guidance on psychedelic research signifies a significant step forward in understanding the therapeutic potential of these substances. The guidance document aims to assist researchers in designing clinical trials that meet the evidentiary standards required for drug development. As interest in psychedelics continues to grow and lawmakers advocate for reform, the FDA’s guidance provides a roadmap for conducting research and advancing the field of psychedelic-assisted therapy. With continued research, legislative support, and regulatory guidance, psychedelic medicines have the potential to revolutionize mental health treatments and provide relief for individuals suffering from mood disorders, anxiety, and addiction.
PSYCHEDELICS GO LEGAL BEFORE WEED, READ ON…
You may like
-
Breaking the Grass Ceiling: Pot firms rethink strategy as young women lead cannabis use
-
California New Laws for 2025: Cannabis Cafes and Entertainment Zones
-
This Company Wants To Pay You To Smoke Marijuana And Write ‘Amazing Reviews’
-
Is it legal to fly with marijuana? Here are the laws you need to know
-
How Much Does an Ounce of Cannabis Flower Cost Entering 2025?
-
New York Governor Signs Bills To Resume Marijuana Farmers Markets And Classify Cannabis As Agricultural Product
Cannabis News
How Do You Stop Lab-Shopping for the Highest THC Results?
Published
15 hours agoon
December 24, 2024By
admin
In a decisive move aimed at bolstering consumer safety and ensuring the integrity of cannabis products, Massachusetts regulators have mandated that all cannabis products must undergo testing at a single, licensed laboratory. This new regulation comes in response to the growing issue of “lab shopping,” where cannabis producers seek favorable testing results by sending their products to multiple laboratories. The Massachusetts Cannabis Control Commission (CCC) announced this significant regulatory change after extensive consultations with industry stakeholders, public health officials, and consumer advocates.
This article explores the implications of this regulation for the cannabis industry, consumers, and public health. It also examines the broader context of cannabis regulation in Massachusetts and the potential impact of this decision on the future of the state’s cannabis market.
Understanding Lab Shopping
What is Lab Shopping?
Lab shopping refers to the practice where cannabis producers send their products to various testing laboratories in search of the most favorable results. Producers may choose labs based on their reputation for leniency or their history of providing positive results. This behavior can lead to significant discrepancies in product safety assessments and quality assurance.
The Risks Associated with Lab Shopping
1. Consumer Health Risks: The primary concern surrounding lab shopping is the potential risk it poses to consumer health. Inconsistent testing results mean that products containing harmful contaminants—such as pesticides, heavy metals, or mold—may be sold without proper scrutiny. This can lead to serious health issues for consumers who unknowingly purchase tainted products.
2. Market Integrity: Lab shopping undermines the integrity of the legal cannabis market. When consumers cannot trust that products have been tested rigorously and uniformly, it erodes confidence in legal cannabis sales and can drive customers back to illicit markets where safety standards are nonexistent.
3. Regulatory Challenges: For regulators like the CCC, lab shopping complicates enforcement efforts. It becomes increasingly difficult to monitor compliance when producers can easily switch labs to obtain favorable results, making it challenging to ensure that all products meet established safety standards.
The Regulatory Response
The Role of the Cannabis Control Commission (CCC)
The Massachusetts Cannabis Control Commission is tasked with regulating the state’s cannabis industry. As part of its mandate, the CCC has worked diligently to establish a comprehensive regulatory framework that governs various aspects of cannabis production and sale. However, as the industry has evolved, so too have the challenges associated with ensuring product safety and quality.
In light of growing concerns about lab shopping and its implications for public health and safety, the CCC recognized the need for a more robust regulatory framework. After extensive discussions with industry stakeholders and public health officials, the commission concluded that a single-lab testing requirement was necessary to address these issues effectively.
Implementation of Single-Lab Testing
In late 2023, following thorough deliberation and stakeholder engagement, the CCC announced its new regulation mandating that all cannabis products must be tested by a single licensed laboratory before they can be sold to consumers. This decision aims to achieve several key objectives:
-
Standardize Testing Protocols: By requiring that all products be tested by a single lab, regulators can ensure that all products are subject to consistent testing standards. This uniformity is crucial for maintaining product quality and safety across the market.
-
Enhance Accountability: A single-lab requirement makes it easier for regulators to hold laboratories accountable for their testing practices. If discrepancies arise in testing results, it will be clear which laboratory conducted the tests, facilitating more straightforward investigations.
-
Improve Consumer Confidence: With consistent testing results across all products, consumers can feel more secure in their purchases. This increased confidence is vital for fostering a healthy legal cannabis market in Massachusetts.
Implications of Single-Lab Testing
For Producers
1. Increased Accountability: Producers will need to establish relationships with specific laboratories and ensure that their products meet stringent quality standards before submission for testing. This shift will require producers to invest more in quality control measures throughout their production processes.
2. Potential Cost Implications: While single-lab testing may streamline processes for some producers, it could also lead to increased costs if producers are required to pay higher fees for comprehensive testing services. Smaller producers may find it particularly challenging to absorb these costs.
3. Adaptation Period: Producers will need time to adjust their operations and supply chains to comply with this new regulation. This may involve reevaluating partnerships with existing labs or investing in new quality control measures.
4. Impact on Product Development: The requirement for single-lab testing may also influence how producers develop new products. With fewer laboratories available for testing, producers may need to plan their product launches more carefully and allow additional time for testing processes.
For Laboratories
1. Increased Demand for Services: Licensed laboratories may experience an increase in demand as producers consolidate their testing needs with fewer facilities. This could lead to higher revenues for labs but also increased pressure on them to maintain high-quality standards amidst growing workloads.
2. Need for Enhanced Capabilities: Laboratories will need to ensure they have the capacity and technology necessary to handle increased volumes of samples while maintaining rigorous quality control measures. This may require investments in new equipment or hiring additional staff.
3. Regulatory Compliance: Laboratories will face heightened scrutiny from regulators as they become key players in ensuring product safety. They will need to demonstrate compliance with all relevant regulations and maintain transparent practices regarding their testing methodologies.
For Consumers
1. Improved Product Safety: The primary benefit for consumers is enhanced safety assurance. With standardized testing protocols in place, consumers can trust that cannabis products have been thoroughly vetted for contaminants and potency before reaching store shelves.
2. Greater Transparency: As part of this regulatory shift, there may be increased transparency regarding testing results and laboratory practices. Consumers will have access to clearer information about what goes into their cannabis products, empowering them to make informed choices.
3. Potential Price Increases: While improved safety is paramount, there is a possibility that compliance costs could be passed on to consumers through higher prices for cannabis products. Producers may need to adjust their pricing structures in response to increased operational costs associated with single-lab testing.
Cannabis Regulation in Massachusetts
Historical Overview
Massachusetts was one of the first states in New England to legalize recreational cannabis use following the passage of Question 4 in 2016. The legalization marked a significant shift in public policy and opened up a new economic sector within the state. However, as with any emerging industry, challenges quickly arose—particularly concerning product safety and quality assurance.
Existing Regulatory Framework
Prior to the introduction of single-lab testing regulations, Massachusetts had established a comprehensive regulatory framework governing various aspects of cannabis production and sale:
Despite these measures, lab shopping highlighted gaps in enforcement and compliance that necessitated further action from regulators.
Industry Reactions
Support from Public Health Advocates
Public health advocates have largely welcomed the CCC’s decision to implement single-lab testing as a crucial step toward safeguarding public health by ensuring that all cannabis products meet consistent safety standards. Many believe this regulation will help prevent contaminated or substandard products from reaching consumers while bolstering trust in legal cannabis sales.
Dr. Emily Thompson, a public health expert at Harvard University, stated, “This regulation is essential for protecting consumers from potential health risks associated with contaminated cannabis products.”
Concerns from Industry Stakeholders
Conversely, some industry stakeholders have expressed concerns about potential drawbacks:
1. Operational Challenges: Smaller producers may find it difficult to navigate relationships with larger laboratories or face delays in getting their products tested due to increased demand at those facilities.
2. Innovation Stifling: Critics argue that requiring single-lab testing could stifle innovation within the industry by limiting producers’ options for exploring different testing methodologies or technologies offered by various labs.
3. Market Dynamics: There are worries that this regulation could create monopolistic tendencies within laboratory services if only a few labs dominate the market due to increased demand from producers seeking reliable test results.
4. Impact on Small Businesses: Small-scale cultivators might struggle more than larger companies due to limited resources and access to high-quality labs capable of meeting stringent requirements without significantly raising costs.
Future Outlook
As Massachusetts implements this new regulation mandating single-lab testing for all cannabis products sold within its borders, it sets an important precedent that other states may consider as they navigate similar challenges within their own burgeoning cannabis markets.
Potential National Implications
The decision by Massachusetts regulators could influence national discussions around cannabis regulation as other states look toward creating frameworks that prioritize consumer safety while fostering industry growth:
-
Increased Interest from Other States: States grappling with similar issues related to lab shopping may look closely at Massachusetts’ approach as they develop their own regulations.
-
Collaboration Among States: As states continue legalizing recreational marijuana use across the country, there may be opportunities for collaboration on best practices regarding product safety standards and laboratory oversight.
-
Federal Considerations: With ongoing discussions about federal legalization of marijuana gaining traction nationally—especially amid shifting political landscapes—regulatory models like those emerging from Massachusetts could serve as templates for future federal guidelines governing cannabis production and sale across state lines.
Conclusion
The Massachusetts Cannabis Control Commission’s mandate for single-lab testing represents a pivotal shift in evaluating cannabis products for safety and quality assurance within one of the nation’s most dynamic legal marijuana markets. By targeting the issue of lab shopping, this regulation prioritizes consumer protection, aiming to enhance public health outcomes and rebuild confidence in the safety of legalized cannabis products. While the transition poses challenges for producers adapting operational processes and laboratories scaling their capabilities, the regulation seeks to balance fostering innovation in an evolving industry with rigorous oversight mechanisms. As Massachusetts refines its regulatory framework, balancing the interests of regulators and profit-driven stakeholders, collaboration will be essential to thriving under these new guidelines. This change not only advances the state’s cannabis sector but also sets a potential standard for other states to ensure safe consumption and responsible business practices in the growing marijuana industry.
LAB SHOPPING FOR HIGH THC RESULTS? READ ON…
Cannabis News
Happy Holidays from The Canna Law Blog
Published
16 hours agoon
December 24, 2024By
admin
Wishing all of our readers, along with friends and families, the very best this holiday season.
Whether you celebrate Hanukkah, Christmas, Kwanzaa, Winter Solstice, Festivus, or something else, we hope you can kick back and enjoy this wonderful time of the year.
The post Happy Holidays from The Canna Law Blog appeared first on Harris Sliwoski LLP.
Cannabis News
5 Cannabis Christmas Recipes to Try This Holiday Season at Home or the Office Party!
Published
2 days agoon
December 23, 2024By
admin
Ah yes, it’s that magical time of year again when Ganja Clause slides down the chimney to visit all the good little stoners. The lights are twinkling, the fire is crackling, and the sweet aroma of cannabis-infused treats fills the air. As someone who’s spent years experimenting with cannabis cuisine, I’ve learned that the holidays present the perfect opportunity to elevate traditional recipes to new heights.
To help make your holidaze more “dazey,” I’ve crafted five festive recipes that combine seasonal favorites with our favorite herb. These dishes aren’t just about getting high – they’re about creating memorable experiences and new traditions. But before we dive in, I need to emphasize something crucial: dosing is always important, and you should NEVER give these recipes to anyone without their explicit consent. While sharing is caring, tricking someone into consuming cannabis is not only unethical but potentially illegal. Always clearly label your infused treats and keep them safely away from children and unsuspecting guests.
With those important notes out of the way, let’s get into these magical recipes that will make your holiday season extra special.
Look, we all know eggnog is a holiday staple, but why not kick it up a notch? This cannabis-infused version will have you feeling jolly in no time. Just remember – this isn’t your grandma’s recipe (unless your grandma is really cool).
What You’ll Need:
-
4 cups milk (or non-dairy alternative if that’s your jam)
-
1 cup heavy cream (or coconut cream for you plant-based folks)
-
6 egg yolks (fresh is best, trust me)
-
1/2 cup sugar
-
1 tsp vanilla extract
-
1/2 tsp ground nutmeg
-
1 tbsp cannabis tincture or cannabis-infused syrup
The Magic Process:
-
Start by heating your milk and cream in a saucepan. You want it hot but not boiling – we’re making eggnog, not scrambled eggs.
-
In a separate bowl, whisk those egg yolks, sugar, and vanilla until they’re well combined and looking smooth.
-
Here’s the tricky part: slowly (and I mean SLOWLY) add the hot milk mixture to your egg mixture while whisking constantly. If you dump it all in at once, you’ll end up with sweet scrambled eggs, and nobody wants that.
-
Pour everything back into your saucepan and cook over medium heat, stirring constantly until it thickens enough to coat the back of a spoon.
-
Remove from heat, stir in that nutmeg, and let it cool a bit before adding your cannabis tincture or syrup.
-
Chill thoroughly before serving.
Pro tip: Start with a small serving – this stuff can creep up on you!
Want to elevate your holiday meal? This gravy will take your feast to new heights. It’s perfect for drowning those mashed potatoes or smothering that turkey.
The Goods:
-
2 cups chicken or vegetable stock
-
1/4 cup all-purpose flour
-
1/4 cup cannabis butter (cannabutter)
-
1/2 tsp salt
-
1/4 tsp black pepper
-
1 tbsp chopped fresh herbs (thyme or rosemary work great)
The How-To:
-
Melt your cannabutter over medium heat in a saucepan. Watch it carefully – burnt butter is not the vibe we’re going for.
-
Whisk in the flour to create your roux. Cook it for about 1-2 minutes to get rid of that raw flour taste.
-
Now, slowly pour in your stock while whisking like your life depends on it. No lumps allowed!
-
Add your seasonings and herbs.
-
Keep stirring and simmering until it reaches your desired thickness.
-
Taste and adjust seasonings if needed (before you get too lifted).
Remember: Label this clearly! You don’t want Aunt Martha accidentally pouring this all over her plate without knowing what’s up.
Forget that canned stuff – this homemade cranberry sauce with a special twist will have everyone at the table asking for seconds (though you might want to limit them to just one serving).
The Ingredients:
Getting Saucy:
-
Toss your cranberries, OJ, and sugar into a saucepan over medium heat.
-
Let it cook until those cranberries start popping like tiny little fireworks (about 10 minutes).
-
Once it’s thickened up nicely, remove from heat.
-
Here comes the fun part – stir in your cannabis-infused honey or tincture.
-
Let it cool completely before serving.
Pro tip: Make two batches – one regular and one infused. Just make sure to label them clearly!
These aren’t your regular sweet potatoes – they’re elevated sweet potatoes. Perfect for getting baked while getting baked.
What You Need:
-
4 large sweet potatoes
-
1/2 cup cannabis butter (cannabutter)
-
1/4 cup brown sugar
-
1 tsp ground cinnamon
-
1/2 tsp ground nutmeg
-
Salt to taste
-
Marshmallows (optional, but highly recommended)
The Method:
-
Preheat your oven to 375°F (190°C).
-
Bake those sweet potatoes until they’re tender (about an hour).
-
Once they’re cool enough to handle, peel and mash them up.
-
Mix in your cannabutter, brown sugar, and spices.
-
Transfer to a baking dish.
-
If you’re feeling extra, top with marshmallows.
-
Bake for another 20-30 minutes until everything’s golden brown and gorgeous.
Warning: These are dangerously delicious – pace yourself!
This warm, spicy cider will lift your spirits in more ways than one. Perfect for those chilly winter nights.
The Essentials:
The Process:
-
Pour your cider into a large pot.
-
Add your cinnamon sticks, cloves, and orange slices.
-
Heat until it just starts to bubble, then reduce to a simmer.
-
Add your cannabis-infused maple syrup (or add tincture to individual cups for controlled dosing).
-
Let everything mingle and get cozy for about 20 minutes.
-
Serve it up warm with an orange slice or cinnamon stick garnish.
Pro tip: Keep a non-infused batch warming for designated drivers and non-partaking guests.
Remember folks, the key to a successful Dankmas feast is clear labeling and careful dosing. Nothing ruins a holiday gathering quite like someone getting unexpectedly zooted. Happy cooking, and may your holidays be dank and delightful!
There you have it, folks – five unique ways to spice up your Dankmas traditions and make the season truly memorable. As someone who’s hosted many cannabis-friendly holiday gatherings, I can’t stress enough the importance of starting slow with these recipes. Edibles can take anywhere from 30 minutes to two hours to fully kick in, and you definitely don’t want to overdo it during family dinner. I strongly recommend doing a test run with different dosages before the big day to find your sweet spot.
What I love most about these recipes is that they offer a fantastic alternative for those looking to skip the traditional alcohol-heavy holiday celebrations. Cannabis provides a more natural way to unwind and connect with loved ones during this special time of year. Plus, you won’t have to worry about a hangover the next morning!
Remember to celebrate responsibly, be open about what’s infused and what isn’t, and most importantly, enjoy the magic of the season. Happy Dankmas to all, and to all a good height!
MORE DANKMAS STORIES, READ ON…
Breaking the Grass Ceiling: Pot firms rethink strategy as young women lead cannabis use
California New Laws for 2025: Cannabis Cafes and Entertainment Zones
This Company Wants To Pay You To Smoke Marijuana And Write ‘Amazing Reviews’
Is it legal to fly with marijuana? Here are the laws you need to know
How Much Does an Ounce of Cannabis Flower Cost Entering 2025?
New York Governor Signs Bills To Resume Marijuana Farmers Markets And Classify Cannabis As Agricultural Product
Cannabis Can Help With Holiday Stomach Issues
How Do You Stop Lab-Shopping for the Highest THC Results?
Happy Holidays from The Canna Law Blog
A New Cannabis Christmas Tradition For Santa
Distressed Cannabis Business Takeaways – Canna Law Blog™
United States: Alex Malyshev And Melinda Fellner Discuss The Intersection Of Tax And Cannabis In New Video Series – Part VI: Licensing (Video)
What you Need to Know
Drug Testing for Marijuana – The Joint Blog
NCIA Write About Their Equity Scholarship Program
It has been a wild news week – here’s how CBD and weed can help you relax
Cannabis, alcohol firm SNDL loses CA$372.4 million in 2022
A new April 20 cannabis contest includes a $40,000 purse
Your Go-To Source for Cannabis Logos and Designs
UArizona launches online cannabis compliance online course
Trending
-
Cannabis News2 years ago
Distressed Cannabis Business Takeaways – Canna Law Blog™
-
One-Hit Wonders2 years ago
United States: Alex Malyshev And Melinda Fellner Discuss The Intersection Of Tax And Cannabis In New Video Series – Part VI: Licensing (Video)
-
Cannabis 1012 years ago
What you Need to Know
-
drug testing1 year ago
Drug Testing for Marijuana – The Joint Blog
-
Education2 years ago
NCIA Write About Their Equity Scholarship Program
-
Cannabis2 years ago
It has been a wild news week – here’s how CBD and weed can help you relax
-
Marijuana Business Daily2 years ago
Cannabis, alcohol firm SNDL loses CA$372.4 million in 2022
-
California2 years ago
A new April 20 cannabis contest includes a $40,000 purse